Litifilimab reduces skin and joint disease in participants with SLE: additional results from Part A of the phase II LILAC study
- DOI
- 10.1136/lupus-2026-002159
- Published
- 2026-07
- Container
- Lupus Science & Medicine
- Publisher
- BMJ
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1136/lupus-2026-002159,
title = {Litifilimab reduces skin and joint disease in participants with SLE: additional results from Part A of the phase II LILAC study},
author = {Ronald F van Vollenhoven and Richard A Furie and Kenneth Kalunian and Victoria P Werth and Jessica Kong and Catherine Barbey and Youmna Lahoud},
year = {2026},
journal = {Lupus Science \& Medicine},
doi = {10.1136/lupus-2026-002159},
url = {https://doi.org/10.1136/lupus-2026-002159}
}RIS
TY - JOUR TI - Litifilimab reduces skin and joint disease in participants with SLE: additional results from Part A of the phase II LILAC study AU - Ronald F van Vollenhoven AU - Richard A Furie AU - Kenneth Kalunian AU - Victoria P Werth AU - Jessica Kong AU - Catherine Barbey AU - Youmna Lahoud PY - 2026 JO - Lupus Science & Medicine DO - 10.1136/lupus-2026-002159 UR - https://doi.org/10.1136/lupus-2026-002159 ER -
APA
Vollenhoven, R. F. V., Furie, R. A., Kalunian, K., Werth, V. P., Kong, J., Barbey, C., & Lahoud, Y. (2026). Litifilimab reduces skin and joint disease in participants with SLE: additional results from Part A of the phase II LILAC study. Lupus Science & Medicine. https://doi.org/10.1136/lupus-2026-002159
Source records
- crossref · retrieved 2026-11-05T22:51:03.714Z